SEC Form 4																
FOR	М 4	UNITED	STATE	S S	ECURITIES				E CO	OMMIS	SION					
					Washingto	.9			OMB APPROVAL							
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					t to Section 16(a) o tion 30(h) of the Inv	es Exchange A		IIP	Estima	Number: ated average burd per response:	3235-0287 en 0.5					
1. Name and Address of Reporting Person*					r Name and Ticker			ationship of Re	Reporting Person(s) to Issuer							
<u>Lucas Svetlana</u>				aTYR PHARMA INC [LIFE]							Director	-)	10% C	wner		
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/26/2023							Officer (giv below)	re title Other below		(specify		
C/O ATYR PHARMA, INC. 10240 SORRENTO VALLEY ROAD, SUITE 300				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) SAN DIEGO	CA	92121										,	e than One Rep			
					Rule 10b5-1(c) Transaction Indication											
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a c satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instru												
	Ta	able I - Nor	n-Derivativ	/e Se	ecurities Acqu	iired,	Disp	osed of, o	r Ben	eficially	Owned					
Date			2. Transactio Date (Month/Day/Y	Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Disposed Of (5)			5. Amount of Securities Beneficially Owned Follo Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Transaction((Instr. 3 and 4			(1130.4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 2. 3. Transaction 3A. Deemed Conversion Date Execution Date, or Exercise (Month/Day/Year) if any 4. 5. Number 6. Date Exercisable and Transaction of Expiration Date Code (Instr. Derivative (Month/Day/Year) 8. Price of Derivative Security 7. Title and Amount of Securities

04/26/2023

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)	action of Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	(2)	04/26/2023		М			6,000	(3)	(3)	Common Stock	6,000	\$0.00	0	D	

M⁽¹⁾

Explanation of Responses:

Common stock

1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.

2. RSUs convert into common stock on a one-for-one basis.

3. The RSUs fully vested one year from the grant date which was April 26, 2022.

Remarks:

/s/ Nancy E. Denyes, attorney-04/28/2023 in-fact

** Signature of Reporting Person Date

Α

(2)

6,000

D

6,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.